CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 527 enrolled
Drug / intervention
Follow-up after 12 weeks after TNF alpha blockers initiationother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03039088
NCT03039088N/ACompleted
CompareCT.gov

PREDICT-SpA - French Epidemiological Study of the Evaluation of the Impact of Fibromyalgia in the TNF Alpha Treatment Effect in Axial Spondyloarthritis in Both Anti-TNF naïve and - Experienced Patients

Association de Recherche Clinique en Rhumatologie·observational·Posted Feb 1, 2017·Updated Sep 19, 2018

In Brief

An observational study evaluating Follow-up after 12 weeks after TNF alpha blockers initiation for Axial Spondyloarthritis and Fibromyalgia. Completed, enrolled 527 participants.

Detailed Summary

This is a prospective observational national (France) study with 2 visits 3 months apart (baseline and 12 weeks after TNF alpha blockers initiation). The objective of recruitment is 500 SpA patients (diagnosis according to their treating rheumatologist) initiating a TNF alpha blocker. The main objective of the study is to evaluate the impact of a concomitant fibromyalgia on the anti-TNF treatment effect in axial Spondyloarthritis in both anti-TNF naïve and pre-exposed patients.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAxial Spondyloarthritis, Fibromyalgia
Countries--
CollaboratorsRCTs

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 1, 2017
Enrollment StartOct 2, 2014
Primary CompletionOct 4, 2016
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 9.4 years ago

Interventions

Follow-up after 12 weeks after TNF alpha blockers initiationother